New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:49 EDTAMAGAMAG sees FY13 COGS of between 14% and 18% of net product sales
AMAG sees FY13 cost of goods sold, COGS, of between 14% and 18% of net product sales; Total operating expenses, excluding COGS, of between $78M and $82M, representing an approximate 10% reduction from 2012. The reduced operating expenses in 2013 will be driven by decreased clinical trial costs, offset in part by new investments in a lower-cost production process and pre-launch investments to support a potential expansion to Feraheme’s label. The company expects: Research and development expenses of between $24M and $27M, representing an approximate 27% reduction from 2012; Selling, general and administrative expenses of between $54M and $57M, representing an approximate 2% increase from 2012.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTAMAGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:20 EDTAMAGAMAG Pharmaceuticals transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use